Scienta is a deeptech company advancing translational research in immunology.

Scienta develops EVA, the first AI foundation model purpose-built for translational prediction in immune-mediated diseases. EVA addresses a critical challenge in pharma R&D: the preclinical–clinical gap, where fewer than 10% of immune drug programs translate successfully to humans.

Built on more than 3 billion multimodal data points across 30 diseases and 70 tissues, EVA uses a biology-first architecture designed to reason like an immunologist. It converts early experimental signals into predicted patient outcomes, with explainable outputs such as pathway-level activity and mechanism-linked biomarkers. Scienta’s approach is scientifically validated  and supported by 18 peer-reviewed publications and 2 patents.

Based at BioLabs Hôtel-Dieu in Paris, Scienta is backed by leading investors, selected among Station F’s Future 40, and named a laureate of the 2025 EIC Accelerator.

Scienta

This office likely focuses on scientific research and AI development, fostering innovation and collaboration among experts.

Scienta

Org chart

Teams

Offices

Scienta

Org chart

Teams

Offices

Related companies